Court Upholds Validity Of J&J's Risperdal Patent
This article was originally published in The Pink Sheet Daily
New Jersey federal court rejects arguments from Mylan and Dr. Reddy's.
You may also be interested in...
While not unexpected, the regulatory delay means the company will have less time to transition patients to the Risperdal follow-on.
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.